Mar. 11 at 11:33 AM
$KMDA Kamada reports Q4 EPS 6c, consensus 8c
Reports q4 revenue
$44.7M vs.
$39M last year. "Our operational and financial performance in 2025 was excellent, with record total revenues of
$180.5 million, representing a 12% year-over-year increase, and record adjusted EBITDA of
$42.0 million, up 23% year-over-year," said Amir London, Kamada's CEO. "Results for the year were well within our 2025 annual guidance, and a testament to our ability to execute on our strategy and generate significant profitable growth through the diversity of our product portfolio. We also demonstrated our ability to convert profitability to operational cash flow, generating
$25.5 million of cash from operating activities for the year, contributing to our strong cash position of
$75.5 million at year-end 2025. We enter 2026 from a position of significant strength, continuing to benefit from growth across our commercial portfolio.
Based on our positive outlook and consistent performance, we affirm our 2026 annual guidance of
$200 million to
$205 million in revenues and
$50 million to
$53 million of adjusted EBITDA, which respectively represent 13% and 23% growth when comparing 2026 guidance mid-points to 2025 results. In 2026, we will focus on the expansion of our entire commercial product portfolio, including continued investment in the commercialization and life cycle management of our six FDA-approved specialty plasma-derived products, supporting organic commercial growth in U.S. and ex-U.S. markets. We also anticipate growth of our Distribution segment through the launch of additional biosimilar products in the Israeli market, as well as the expansion of the Distribution business to the MENA region.
We further expect to continue ramping up plasma collection in our three plasma centers with the aim of strengthening our vertical integration, reducing specialty plasma costs and supporting continued growth through sales of normal-source plasma. Lastly, we aim to secure new business development and M&A transactions, which will accelerate our profitable growth and expect these transactions to enrich our current portfolio of marketed products and generate synergies with our existing commercial operations," concluded Mr. London.
